Change Country
Welcome to LuxembourgWelcome
Please read the important information below before continuing to our website

The Lyxor ETFs on this website may be restricted for certain individuals or in certain countries pursuant to the national regulations applicable to those individuals or countries. It is therefore your responsibility to ensure that you are authorised to invest in the Lyxor ETFs on this website. 


If you are an investor in the United Kingdom, please go to  

If you are an investor in the Netherlands, please go to  

If you are an investor in Italy, please go to  

If you are an investor in Spain, please go to  

If you are an investor in Austria, please go to  

If you are an investor in Germany, please go to   

If you are an investor in Singapore, please go to  

If you are an investor in Switzerland, please go to  

If you are an investor in Belgium, please go to  

If you are an investor in Poland, please go to 

If you are an investor in Norway, please go to

If you are an investor in Denmark, please go to

If you are an investor in Luxembourg, please go to

If you are an investor in Sweden, please go to

If you are an investor in Finland, please go to



The Lyxor ETFs on this website are undertakings for collective investment in transferable securities (UCITS) (i) domiciled in France and approved by the Autorité des Marchés Financiers (AMF) or, (ii) domiciled in Luxembourg, approved by the Commission de Surveillance du Secteur Financier (CSSF) and authorised to market their units or shares in the French Republic in accordance with the notification procedure under Article 93 of Directive 2009/65/EC. Investors should note that the prospectuses of certain Lyxor ETFs under Luxembourg law that have been notified in accordance with this procedure are only available on the website in English. A French translation of these prospectuses can be obtained upon request by sending a letter to Lyxor International Asset Management (“Lyxor”) – 17 Cours Valmy, 92987 Paris La Défense, France.


The information on this website is not intended for persons or entities that are resident, located or registered in jurisdictions that are not authorised to distribute Lyxor ETFs. As a result, the information on this website does not constitute an offer or solicitation to buy or sell units or shares in these ETFs by anyone in any jurisdiction:


(a)   in which such an offer or solicitation is unauthorised;

(b)   in which Lyxor is not qualified to make such an offer or solicitation; or 

(c)   in which it is unlawful to make such an offer or solicitation.


In particular, the Lyxor ETFs on this website are not and will not be registered under the United States Securities Act of 1933, as amended. As such, they may not be offered or sold within the United States of America, except in specific cases where transactions are exempt from registration under the Securities Act. The ETFs listed on this website may not be sold to US citizens or transferred to the United States by any other means, unless this transaction is not subject to any specific registration under US law. 


Any person from a jurisdiction to which the above-mentioned restrictions apply should inform themselves of and observe these restrictions.


This website is intended for commercial purposes and is not regulatory in nature. Although the information provided has been drawn up on the basis of sources considered to be reliable, there is no guarantee that it is accurate, complete or relevant. Some of the information on this website is provided on the basis of market data collected at a specific time and may therefore vary over time. Lyxor advises investors to read the risk factors section of the prospectus and the key investor information document carefully. These documents can be found on the website.


The net asset value (“NAV”) of Lyxor ETFs may at any time be subject to considerable price fluctuations, which in some cases may lead to the loss of all of the capital invested. Investors should note that some ETFs may be sensitive to fluctuations in the exchange rate between their reference currency and that of the underlying index, as well as of the components of the underlying index.


Before investing in a Lyxor ETF, you should carry out your own risk analysis of the product from a legal, tax and accounting perspective, rather than basing your decision solely on the information provided. If necessary, you should consult your own advisers or any other qualified professional. 


Subject to compliance with the legal obligations by which they are bound, Lyxor or any entity within the same group shall not be held liable for any financial or other consequences of an investment in the product. 



By clicking on institutional or individual above, I confirm that I have read and understood the information provided herein, and that I am resident or registered in Luxembourg.


08 Dec 2017

2018: Little to gain, lots to lose?


After all the market exuberance of 2017, what’s next? A series of record highs leaves everything feeling a bit “toppish” as we end the year, especially with central banks heading for the QE exits.   

Global equity valuations: reaching a ceiling? 

global equity valuations graph

Source: World Federation of Exchanges, OECD, and national sources. Data as of Sep-2017 (there is a delay in the publications of World Federation of Exchanges). Countries in the sample are US, Japan, Germany, UK, Switzerland, South Africa, South Korea and Taiwan.

We’re not calling a crash, not yet anyway, but complacency could be dangerous despite seemingly synchronised global growth. After all, equity market volatility has dropped below that of bonds for the first time ever this year.

Whether you’re a bull readying for one last run or a bear just waking from hibernation, we’ve got you covered. 


What’s on your horizon?

Here’s a quick summary of the themes we expect to see moving markets next year:

1. QE exit strategies    

We are, finally, “nearing normal”, with central banks set to move further away from their super accommodative policies. Illiquid, expensive assets could suffer – especially in yield, and especially if global growth does peak in the latter part of 2018.

QE exit strategies mean it could be time to consider preparing your portfolio to dampen the effects of certain events – like rising inflation and rates, market volatility and currency movements. The fairytale could finally be coming to an end. 

2. Finally, a fiscal push!    

It’s not all doom & gloom by any means – there are opportunities if you are agile enough to seek them out.  True, there may not be much upside for broad equity indices, especially in the US. But one of the grand global themes for 2018 will be the rise in CAPEX, whether in Europe, the US or Asia. Companies are more willing (or more incentivised) to invest more of the cash they’ve been hoarding in recent years and that could have its benefits.

Tax reform in the US will add to the momentum. Overall, the bill should boost the dollar (albeit relatively briefly) and equities and push up bond yields. In the short term, winners could include small-caps, retail, and possibly financials – although much could already be priced in. Highly indebted companies will however struggle with the limits imposed on interest deductions. Trump’s track record on political management isn’t great, meaning these benefits may be fleeting so you’ll need to be fleet of foot.

In fact, adopting a more nimble approach & selecting the areas set to do best may be more rewarding than holding firm to existing allocations. All this investment could bode well for commodities and infrastructure as well as sectors like construction and technology for example. 

3. Exploiting Europe’s differences  

Differentiation and divergence will become more apparent between markets as well as asset classes. The US recovery is maturing, and all eyes will be on signs of a possible slowdown as we move through 2018. The recoveries in Europe and Japan have room to run yet.

A word of caution though - European markets are now back in line with their long-term averages, so it’s time to dig a bit deeper and support key themes like the recovering consumer and financials. Banking sector risks may be subsiding, but there are others on the horizon.  Politics is still crucial, with the potential fall-out from Catalan elections, Italy’s own election and Brexit all in focus. There are issues in Germany too.

For all that, “Macronomic” progress, the likely need for stimulus spending to secure a coalition in Germany and the general recovery story keep us keen. We favour France and Germany, given potential ECB policy changes and political gridlock cloud the outlook for Italy and Spain. The FTSE 100 faces its own Brexit battles. We do however expect fears to fade and for risks to migrate to the US over the course of H2.

4. Firing Asian arrows​

In Asia, Japan’s improving structural story keeps us positive on the land of the rising sun – especially given the likelihood of another four years of Abe’s loose policy mix. Meanwhile, Xi Jinping’s ever stronger grip on power in China seems to guarantee stability. We can’t see Chinese equities having quite such a stellar year though. Emerging Asian markets should benefit once the dollar resumes its downwards trend. We like Korea and the ASEAN region; in part because they add an element of protection should markets re-correlate in the wake of any US equity correction. We are less positive on India and Taiwan for now.

5. Bond yields to rise​

When it comes to bonds, there’s not much to gain either. Yields are likely to rise everywhere from here (although we’re not calling a market implosion!), but 10yr US Treasuries may still be something of a safe haven. Credit – notably high yield - looks expensive and unappealing. We do however like breakeven stories, starting with the US late this year, early next. Our support could migrate to eurozone issues late in 2018.

Watch this space for much more on these themes and the way to play them in January. Until then, thanks for reading, and seasons greetings! 

Risk Warning 


Fund and charge data: Lyxor ETF, correct as at 06 December 2017.

This document is for the exclusive use of investors acting on their own account and categorized either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2004/39/EC. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on, and upon request to

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Lyxor International Asset Management (LIAM), société par actions simplifiée having its registered office at Tours Société Générale, 17 cours Valmy, 92800 Puteaux (France), 418 862 215 RCS Nanterre, is authorized and regulated by the Autorité des Marchés Financiers (AMF) under the UCITS Directive (2009/65/EU) and the AIFM Directive (2011/31/EU). LIAM is represented in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

Research disclaimer 

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures and disclaimers. Alternatively, visit our global research disclosure website

CONFLICTS OF INTEREST This research contains the views, opinions and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin